
    
      The maximum study duration per patient will be approximately 33 weeks: an up to 2-week
      screening period (it can be exceptionally extended up to one additional week), a 30-week,
      open label randomized treatment period comparing iGlarLixi to insulin glargine (Â± metformin
      for both treatments), and a 3-day post-treatment safety follow-up period.
    
  